The metastatic spread of breast cancer to the leptomeninges (LM) is a painf
ul, debilitating, and usually lethal condition. Current therapies are gener
ally ineffective or extremely toxic, The current study evaluated monoclonal
antibody therapy in an animal model of LM human breast cancer, Monoclonal
antibody 4D5, which recognizes the extracellular domain of the HER2/neu rec
eptor, was administered into the cerebrospinal fluid of athymic rats implan
ted with human breast cancer cell lines. Continuous intraventricular admini
stration of 4D5 inhibited growth of SKBR3 cells that overexpress HER2/neu b
ut not of MCF7 cells, which do not. Inhibition was dose-dependent, with hig
her doses of 4D5 producing an improved response. i.p. administration of cis
platin in addition to 4D5 did not improve results, Continuous administratio
n of 4D5 into the lumbar, as opposed to the ventricular intrathecal space,
was not therapeutically effective. Treatment with 4D5 did not result in out
growth of cells lacking expression of the HER2/neu receptor. These results
suggest that 4D5, administered regionally, may palliate LM metastases from
HER2/neu-over-expressing breast carcinoma.